Between 2015 and 2019, the rate of SGLT2 inhibitor use increased for the management of type 2 diabetes, yet overall use remained low, including for patients with HFrEF, ASCVD, and CKD. This evidence concerns the gene SLC5A2 and chronic kidney disease.